You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population
|
|---|---|
| Published in |
Journal of Hepatology, August 2016
|
| DOI | 10.1016/j.jhep.2016.08.004 |
| Pubmed ID | |
| Authors |
Hamish Innes, Scott McDonald, Peter Hayes, John F. Dillon, Sam Allen, David Goldberg, Peter R. Mills, Stephen T. Barclay, David Wilks, Heather Valerio, Ray Fox, Diptendu Bhattacharyya, Nicholas Kennedy, Judith Morris, Andrew Fraser, Adrian Stanley, Peter Bramley, Sharon J. Hutchinson |
| Abstract |
The number of people living with previous hepatitis-C infection that have attained a sustained viral response (SVR) is expected to grow rapidly. So far, the prognosis of this group relative to the general population is unclear. Individuals attaining SVR in Scotland in 1996-2011 were identified using a national database. Through record-linkage, we obtained cause-specific mortality data complete to Dec 2013. We calculated standardised-mortality-ratios (SMRs) to compare the frequency of mortality in SVR patients to the general population. In a parallel analysis, we used Cox regression to identify modifiable patient characteristics associated with post-SVR mortality. We identified 1824 patients, followed on average for 5.2 years after SVR. In total, 78 deaths were observed. Overall, all-cause mortality was 1.9 times more frequent for SVR patients than the general population (SMR: 1.86; 95% CI:1.49-2.32). Significant cause-specific elevations were seen for death due to primary liver cancer (SMR: 23.50; 95% CI:12.23-45.16), and death due to drug-related causes (SMR: 6.58, 95%CI:4.15-10.45). Together these two causes accounted for 66% of the total excess death observed. All of the modifiable characteristics associated with increased mortality were markers either of heavy alcohol use or injecting drug use. Individuals without these behavioural markers (32.8% of cohort) experienced equivalent survival to the general population (SMR: 0.70; 95% CI:0.41-1.18) CONCLUSIONS: Mortality in Scottish SVR patients is higher overall than the general population. The excess was driven by death from drug-related causes and liver cancer. Health risk behaviours emerged as important modifiable determinants of mortality in this population. Patients cured of hepatitis C through treatment had a higher mortality rate overall than the general population. Most of the surplus mortality was due to drug-related causes and death from liver cancer. A history of heavy alcohol use and injecting drug use were associated with a higher mortality risk. |
X Demographics
The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 16% |
| Spain | 4 | 13% |
| United Kingdom | 3 | 9% |
| Switzerland | 2 | 6% |
| Australia | 1 | 3% |
| Malaysia | 1 | 3% |
| Canada | 1 | 3% |
| Uganda | 1 | 3% |
| Uruguay | 1 | 3% |
| Other | 5 | 16% |
| Unknown | 8 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 66% |
| Practitioners (doctors, other healthcare professionals) | 8 | 25% |
| Scientists | 2 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 1% |
| Unknown | 67 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 19% |
| Student > Ph. D. Student | 8 | 12% |
| Other | 6 | 9% |
| Professor > Associate Professor | 6 | 9% |
| Student > Master | 6 | 9% |
| Other | 14 | 21% |
| Unknown | 15 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Nursing and Health Professions | 3 | 4% |
| Earth and Planetary Sciences | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Other | 2 | 3% |
| Unknown | 21 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2017.
All research outputs
#1,356,056
of 25,374,647 outputs
Outputs from Journal of Hepatology
#724
of 6,276 outputs
Outputs of similar age
#24,461
of 354,572 outputs
Outputs of similar age from Journal of Hepatology
#18
of 110 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,276 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,572 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 110 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.